Obesity Drug Progress: Recent chatter on social media has centered on Viking Therapeutics’ promising developments with its obesity drug candidate, VK2735. Many users are excited about the Phase 2 VENTURE trial results, which showed significant weight loss, sparking optimism about its potential market impact. The prospect of an oral drug as a competitor to injections has also fueled enthusiastic discussions.
Acquisition Speculation: Another hot topic online is the growing interest in Viking as a potential acquisition target. Posts highlight the CEO’s comments on a broader appetite for weight-loss drug deals, with some speculating about an imminent buyout or partnership. This has added a layer of intrigue to the ongoing conversation around the stock’s future.
Note: This discussion summary was generated from an AI condensation of post data.
Viking Therapeutics Insider Trading Activity
Viking Therapeutics insiders have traded $VKTX stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:
- BRIAN LIAN (President & CEO) has made 0 purchases and 5 sales selling 272,398 shares for an estimated $9,057,043.
- CHARLES A JR ROWLAND sold 60,000 shares for an estimated $2,134,278
- MARIANNA MANCINI (Chief Operating Officer) has made 0 purchases and 5 sales selling 63,846 shares for an estimated $2,117,897.
- GREG ZANTE (Chief Financial Officer) has made 0 purchases and 5 sales selling 63,846 shares for an estimated $2,113,449.
- MATTHEW W FOEHR sold 16,000 shares for an estimated $561,694
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Viking Therapeutics Hedge Fund Activity
We have seen 194 institutional investors add shares of Viking Therapeutics stock to their portfolio, and 176 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 4,031,846 shares (-41.0%) from their portfolio in Q3 2025, for an estimated $105,956,912
- CITADEL ADVISORS LLC added 1,025,367 shares (+117.5%) to their portfolio in Q3 2025, for an estimated $26,946,644
- TWO SIGMA INVESTMENTS, LP added 771,704 shares (+58.7%) to their portfolio in Q3 2025, for an estimated $20,280,381
- STATE STREET CORP added 738,141 shares (+19.5%) to their portfolio in Q3 2025, for an estimated $19,398,345
- PICTET ASSET MANAGEMENT HOLDING SA removed 720,569 shares (-37.6%) from their portfolio in Q3 2025, for an estimated $18,936,553
- BRAIDWELL LP removed 678,100 shares (-47.2%) from their portfolio in Q3 2025, for an estimated $17,820,468
- FRONTIER CAPITAL MANAGEMENT CO LLC removed 638,204 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $16,772,001
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Viking Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $VKTX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 10/29/2025
- JP Morgan issued a "Overweight" rating on 10/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/29/2025
- Raymond James issued a "Strong Buy" rating on 07/24/2025
To track analyst ratings and price targets for Viking Therapeutics, check out Quiver Quantitative's $VKTX forecast page.
Viking Therapeutics Price Targets
Multiple analysts have issued price targets for $VKTX recently. We have seen 7 analysts offer price targets for $VKTX in the last 6 months, with a median target of $102.0.
Here are some recent targets:
- Edward Nash from Canaccord Genuity set a target price of $107.0 on 11/12/2025
- Hardik Parikh from JP Morgan set a target price of $75.0 on 10/24/2025
- Michael Ulz from Morgan Stanley set a target price of $102.0 on 10/23/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $102.0 on 09/29/2025
- Justin Zelin from BTIG set a target price of $125.0 on 09/22/2025
- David Lebowitz from Citigroup set a target price of $38.0 on 07/24/2025
- Ryan Deschner from Raymond James set a target price of $122.0 on 07/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
